Health ProductsDear Healthcare Professional Letter

Archived – Association of Tazocin® (Piperacillin/Tazobactam) with False Positive Results of the Bio-Rad Aspergillus Assay

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Wyeth Pharmaceuticals Canada
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on BIO-RAD ASPERGILLUS ASSAY and TAZOCIN® (piperacillin/tazobactam)

Hospitals
Laboratories
Physicians

January 22, 2004

Dear Healthcare Professional:

SUBJECT: New information regarding a Bio-Rad aspergillus assay interaction with Tazocin® (piperacillin/tazobactam)

The purpose of this letter is to communicate information regarding a Bio-Rad Aspergillus assay interaction with piperacillin/tazobactam.

There have been reports of false positive test results using the Bio-Rad Laboratories Platelia Aspergillus enzyme immunoassay (EIA) test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic tests.

We have already updated our Tazocin® Complete Prescribing Information (CPI) to include the statement in the preceding paragraph regarding the laboratory test interaction. This update will be implemented with our next printing. The safety and efficacy of Tazocin remain unchanged.

The following is presented as background information.

Bio-Rad Laboratories Platelia Aspergillus EIA is designed to detect galactomannan, a complex sugar found in the Aspergillus cell wall. Galactomannan is a non-infectious, non-pyrogenic carbohydrate. However, there are other sources of galactomannan, including starches (such as rice, vegetables and pasta) or fungi (such as Penicillium and Paecilomyces). In published literature, some investigators have speculated that there may be translocation of galactomannan antigen found in various foodstuffs through damaged intestinal mucosa (mucositis).Footnote 1,Footnote 2

The assay is a blood test intended to screen at-risk patients for Aspergillus infection. A positive reaction to this test could be indicative of a possible (but not definitive) Aspergillus infection. Adult "false positive" rates of 8% and 14%, and a rate of 44% in children, have been reported. According to Bio-Rad, Platelia Aspergillus EIA should be considered in conjunction with other diagnostic procedures such as microbiological culture, histological examination of biopsy samples and radiographic evidence. Therefore, a positive result should be interpreted cautiously and confirmed by other diagnostic methods.

Two European investigators presented their experience with the Bio-Rad Platelia Aspergillus EIA test performed on high-risk patients at the Interscience Conference on Antimicrobial Agents and Chemotherapy (September 2003). Routine testing was performed twice weekly on serum from patients at risk of invasive aspergillosis. Both researchers reported a higher rate of positive results in patients treated with piperacillin/tazobactam than they had noted in patients treated with other antimicrobials. However, further investigation did not confirm the presence of Aspergillus infection, and therefore, tests were "falsely positive" for Aspergillus infection in these patients. The investigators also reported several piperacillin/tazobactam vials tested positive for galactomannan.

Piperacillin/tazobactam vials from the same batches have been rigorously tested by Wyeth for microbiological contamination and were reconfirmed to be sterile and Aspergillus-negative. Therefore, it is likely that a non-Aspergillus carbohydrate chain is cross-reacting with the Platelia antibody. Wyeth continues to work to determine the cause of the cross-reactivity.

If you have any questions about this information or you wish to report an adverse event, please contact Wyeth Medical Information or the Marketed Health Products Directorate at the following addresses:

Wyeth Canada
Medical Information & Pharmacovigilance
50 Minthorn Boulevard
Markham, Ontario L3T 7Y2
Tel: 1-800-461-8844
Fax: (905) 470-4385

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

Sincerely,

original signed by

Neil Maresky, M.B., B.Ch.
Vice President
Scientific Affairs

Footnotes

Footnotes 1

Letscher-Bru V, Cavalier A, Pernot-Marino E, et al. Aspergillus galactomannan antigen detection with Platelia®. J Mycologie Medical. 1998;8:112-113.

Return to footnote 1 referrer

Footnotes 2

Hamaki T, Kami M, Kanda Y, et al. False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:633-634.

Return to footnote 2 referrer

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime